– 26 scientific abstracts, including two oral presentations, demonstrate UCB s ongoing commitment to advancing research for people living with epilepsies
– Data include an open-label extension study describing the long-term safety of FINTEPLA®? (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2]
– Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic cha
Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines.
Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company s newly established Cambridge location, where he will establish a group of world-class biomedical talent as the company advances its work translating AI-driven drug discovery
BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic science to clinical trials.
BIAL will be presenting the ACTIVATE study, a Phase II trial evaluating the effic
ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.
This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.
A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant under the EIC Transition Programme of Horizon Europe.
The funding will drive the consortium s collaborative efforts to develop NeutroFlow—a novel, point-of-care diagnostic test designed to predict patient response to immune checkpoint inhibitors (ICIs) acros
– Revenues +11.6%, Adjusted EBITDA +13.1%
– Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3%
– Q1 significantly influenced by revenue shift in syringe business
– Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of 22%
Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, recorded a jump in revenues and earnings due to the first-time cons
MidEuropa, a leading private equity investor with deep roots in Central Europe, announces that its portfolio company, Diagnostyka, a leading provider of medical diagnostic services in Poland, has debuted on the Warsaw Stock Exchange on Friday, February 7, 2025.
The market closing price on the first day of trading puts Diagnostyka s market capitalisation at over €1 billion. Diagnostyka thus ranks as the second-largest publicly listed healthcare services provider in Central Europe and among
Back to media releases (https://norgine.com/media)
Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i
Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee s Oral Delivery of Biologics Platform at the 14th Annual PODD Conference – Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024.
Presentation Title: "Breakthrough Device for Oral Delivery of Biologics".
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/uploads/716035.jpg "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma")